Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sotagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 known ✓ | P13866 | 14/20 | 1.00 |
| ▸ | SLC5A2 known ✓ | P31639 | 14/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sotagliflozin SCHEMBL17036778 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL1038287 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL19512410 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL10267817 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL19853184 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| Sotagliflozin SCHEMBL23731430 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL16234522 | 0.92 | SLC5A2 (0.85) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL23077583 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2 | |
| SCHEMBL1036755 | 0.91 | SLC5A2 (0.83) | SLC5A1SLC5A2ADRA2ASLC5A11 | |
| SCHEMBL20787163 | 0.89 | SLC5A1 (1.00) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015376-A | SGLT-1 inhibitors and uses thereof | 密执安大学评议会 | 2023-11-07 | — | — | CN | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| CN-122055157-A | Method for reducing the risk of cardiovascular events in patients with left ventricular hypertrophy | 莱西肯医药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12582631-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4676931-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| CN-109195980-B | Novel crystal form of sodium-glucose cotransporter inhibitor drug, preparation method and application thereof | 苏州科睿思制药有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220143003-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. | 2022-05-12 | — | — | US | disclosed |
| EP-3986417-A1 | SPHINGOLIPIDS FOR GENERATING REGULATORY CD4+ T CELLS | Deutsches Krebsforschungszentrum (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-114269728-A | Continuous process for preparing crystalline form II sogelliflozin | 莱西肯医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114258397-A | Process for preparing crystalline form II soxhlet | 莱西肯医药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220088144-A1 | SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY | UNIVERSITÄTSSPITAL BASEL (CH) | 2022-03-24 | — | — | US | disclosed |
| WO-2022051316-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A SGLT-2 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-114051409-A | For generating regulatory CD4+T cell sphingolipids | 德国癌症研究中心 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143003-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | GLP1R, SLC5A1, SLC5A2 | SLC5A1 2/4885SLC5A2 3/4885ADRA2A 893/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | SLC5A1 46/4885SLC5A2 65/4885ADRA2A 800/4885 |
| US-12582631-B2 | Methods of improving renal function | LGALS1, LGALS9, REN | SLC5A1 10/4885SLC5A2 17/4885ADRA2A 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.